Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
Abstract Potential CD19 antigen loss following CD19-directed therapy has raised concerns over sequential use of these therapies. Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, is approved for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) treatment in adul...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Biomarker Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40364-024-00706-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585486372175872 |
|---|---|
| author | Narendranath Epperla Loretta J. Nastoupil Bruce Feinberg John Galvin Prathamesh Pathak Theresa Amoloja Danielle Gentile Kim Saverno |
| author_facet | Narendranath Epperla Loretta J. Nastoupil Bruce Feinberg John Galvin Prathamesh Pathak Theresa Amoloja Danielle Gentile Kim Saverno |
| author_sort | Narendranath Epperla |
| collection | DOAJ |
| description | Abstract Potential CD19 antigen loss following CD19-directed therapy has raised concerns over sequential use of these therapies. Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, is approved for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) treatment in adults ineligible for autologous stem cell transplantation. This retrospective analysis examined characteristics and outcomes of adults with R/R DLBCL who received tafasitamab preceding CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy in a real-world setting. Nine patients received tafasitamab and lenalidomide immediately preceding CAR-T. Median (first quartile [Q1]–third quartile [Q3]) follow-up time since tafasitamab initiation was 26.1 (18.0–28.0) and after CAR-T was 9.3 (1.9–16.7) months. Of the 9 patients, 4 had complete response, 4 had partial response, and 1 had stable disease following tafasitamab; all discontinued tafasitamab due to disease progression. Median (Q1–Q3) tafasitamab therapy duration was 11.0 (8.1–14.1) months. Three patients had CD19 testing following tafasitamab discontinuation, and all tests were positive. Median (Q1–Q3) time from tafasitamab discontinuation to CD19 testing was 7 (6–9) days. Among the 9 patients, median (Q1–Q3) time from tafasitamab discontinuation to CAR-T administration was 3.2 (2.3–3.6) months. Four patients had complete response, 3 had partial response, and 1 had progressive disease as best response to CAR-T; 1 patient had data unavailable. This small real-world analysis demonstrated disease response to CAR-T therapy and detectable CD19 expression following tafasitamab treatment, adding to literature investigating treatment outcomes associated with sequential use of anti-CD19 therapies in patients with R/R DLBCL. |
| format | Article |
| id | doaj-art-415460a9c4954cd49ab3b8ae50d28165 |
| institution | Kabale University |
| issn | 2050-7771 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Biomarker Research |
| spelling | doaj-art-415460a9c4954cd49ab3b8ae50d281652025-01-26T12:45:42ZengBMCBiomarker Research2050-77712025-01-011311510.1186/s40364-024-00706-6Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphomaNarendranath Epperla0Loretta J. Nastoupil1Bruce Feinberg2John Galvin3Prathamesh Pathak4Theresa Amoloja5Danielle Gentile6Kim Saverno7Huntsman Cancer Institute, University of UtahThe University of Texas MD Anderson Cancer CenterCardinal HealthIncyte CorporationCardinal HealthIncyte CorporationCardinal HealthIncyte CorporationAbstract Potential CD19 antigen loss following CD19-directed therapy has raised concerns over sequential use of these therapies. Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, is approved for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) treatment in adults ineligible for autologous stem cell transplantation. This retrospective analysis examined characteristics and outcomes of adults with R/R DLBCL who received tafasitamab preceding CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy in a real-world setting. Nine patients received tafasitamab and lenalidomide immediately preceding CAR-T. Median (first quartile [Q1]–third quartile [Q3]) follow-up time since tafasitamab initiation was 26.1 (18.0–28.0) and after CAR-T was 9.3 (1.9–16.7) months. Of the 9 patients, 4 had complete response, 4 had partial response, and 1 had stable disease following tafasitamab; all discontinued tafasitamab due to disease progression. Median (Q1–Q3) tafasitamab therapy duration was 11.0 (8.1–14.1) months. Three patients had CD19 testing following tafasitamab discontinuation, and all tests were positive. Median (Q1–Q3) time from tafasitamab discontinuation to CD19 testing was 7 (6–9) days. Among the 9 patients, median (Q1–Q3) time from tafasitamab discontinuation to CAR-T administration was 3.2 (2.3–3.6) months. Four patients had complete response, 3 had partial response, and 1 had progressive disease as best response to CAR-T; 1 patient had data unavailable. This small real-world analysis demonstrated disease response to CAR-T therapy and detectable CD19 expression following tafasitamab treatment, adding to literature investigating treatment outcomes associated with sequential use of anti-CD19 therapies in patients with R/R DLBCL.https://doi.org/10.1186/s40364-024-00706-6CAR-TCD19Chimeric antigen receptor T-cellR/R DLBCLReal-world studyTafasitamab |
| spellingShingle | Narendranath Epperla Loretta J. Nastoupil Bruce Feinberg John Galvin Prathamesh Pathak Theresa Amoloja Danielle Gentile Kim Saverno Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma Biomarker Research CAR-T CD19 Chimeric antigen receptor T-cell R/R DLBCL Real-world study Tafasitamab |
| title | Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma |
| title_full | Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma |
| title_fullStr | Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma |
| title_full_unstemmed | Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma |
| title_short | Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma |
| title_sort | real world use of tafasitamab preceding cd19 directed chimeric antigen receptor t cell therapy for relapsed or refractory diffuse large b cell lymphoma |
| topic | CAR-T CD19 Chimeric antigen receptor T-cell R/R DLBCL Real-world study Tafasitamab |
| url | https://doi.org/10.1186/s40364-024-00706-6 |
| work_keys_str_mv | AT narendranathepperla realworlduseoftafasitamabprecedingcd19directedchimericantigenreceptortcelltherapyforrelapsedorrefractorydiffuselargebcelllymphoma AT lorettajnastoupil realworlduseoftafasitamabprecedingcd19directedchimericantigenreceptortcelltherapyforrelapsedorrefractorydiffuselargebcelllymphoma AT brucefeinberg realworlduseoftafasitamabprecedingcd19directedchimericantigenreceptortcelltherapyforrelapsedorrefractorydiffuselargebcelllymphoma AT johngalvin realworlduseoftafasitamabprecedingcd19directedchimericantigenreceptortcelltherapyforrelapsedorrefractorydiffuselargebcelllymphoma AT prathameshpathak realworlduseoftafasitamabprecedingcd19directedchimericantigenreceptortcelltherapyforrelapsedorrefractorydiffuselargebcelllymphoma AT theresaamoloja realworlduseoftafasitamabprecedingcd19directedchimericantigenreceptortcelltherapyforrelapsedorrefractorydiffuselargebcelllymphoma AT daniellegentile realworlduseoftafasitamabprecedingcd19directedchimericantigenreceptortcelltherapyforrelapsedorrefractorydiffuselargebcelllymphoma AT kimsaverno realworlduseoftafasitamabprecedingcd19directedchimericantigenreceptortcelltherapyforrelapsedorrefractorydiffuselargebcelllymphoma |